Financial Review: AtriCure (NASDAQ:ATRC) & Ansell (OTCMKTS:ANSLF)

Posted by MarketBeat News on Oct 21st, 2023

AtriCure (NASDAQ:ATRC – Get Free Report) and Ansell (OTCMKTS:ANSLF – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Valuation & Earnings

This table compares AtriCure and Ansell’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$330.38 million	5.10	-$46.47 million	($0.61)	-58.29
Ansell	N/A	N/A	N/A	$0.31	43.80

Ansell has lower revenue, but higher earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Ansell, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

Want More Great Investing Ideas?

This is a summary of recent ratings and target prices for AtriCure and Ansell, as provided by MarketBeat.

Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0	0	5	0	3.00
Ansell	0	0	0	0	N/A

AtriCure currently has a consensus target price of $65.00, suggesting a potential upside of 82.79%. Given AtriCure’s higher possible upside, analysts clearly believe AtriCure is more favorable than Ansell.

Profitability

This table compares AtriCure and Ansell’s net margins, return on equity and return on assets.

Net Margins	Return on Equity	Return on Assets
AtriCure	-7.67%	-7.11%	-5.54%
Ansell	N/A	N/A	N/A

Institutional and Insider Ownership

94.3% of AtriCure shares are held by institutional investors. Comparatively, 39.0% of Ansell shares are held by institutional investors. 3.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

About AtriCure

(Get Free Report)

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

About Ansell

(Get Free Report)

Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates in two segments, Healthcare and Industrial. The Healthcare segment manufactures and markets solutions comprising surgical gloves, single use and examination gloves, and clean and sterile gloves and garments, as well as consumables used by hospitals, surgical centers, dental practices, veterinary clinics, first responders, manufacturers, auto repair shops, chemical plants, laboratories, and life sciences and pharmaceutical companies. The Industrial segment manufactures and markets hand and chemical protective clothing solutions for a range of industrial applications, including automotive, chemical, metal fabrication, machinery and equipment, food, construction, mining, oil and gas, utilities, logistics, and first responders. The company was formerly known as Pacific Dunlop Limited and changed its name to Ansell Limited in 2002. Ansell Limited was founded in 1893 and is based in Richmond, Australia.

Receive News & Ratings for AtriCure Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.